Please wait
S-8 EX-FILING FEES 0001912966 Fees to be Paid Fees to be Paid Fees to be Paid N/A 0001912966 1 2026-08-09 2026-08-09 0001912966 2 2026-08-09 2026-08-09 0001912966 3 2026-08-09 2026-08-09 0001912966 2026-08-09 2026-08-09 iso4217:USD xbrli:pure xbrli:shares

Ex-Filing Fees

CALCULATION OF FILING FEE TABLES

S-8

Regentis Biomaterials Ltd.

Table 1: Newly Registered Securities

                                       
Security Type   Security Class Title   Notes   Fee Calculation
Rule		   Amount Registered   Proposed Maximum Offering
Price Per Unit		   Maximum Aggregate Offering Price   Fee Rate   Amount of Registration Fee
                                       
Equity   Ordinary Shares, no par value per share, reserved for issuance pursuant to the 2024 Share Option Plan   (1)   Other   500,000   $ 1.9475   $ 973,750.00   0.0001381   $ 134.47
Equity   Ordinary Shares, no par value per share, reserved for issuance pursuant to options outstanding under the 2024 Share Option Plan   (2)   Other   1,150,132     1.9475     2,239,882.07   0.0001381     309.33
Equity   Ordinary Shares, no par value per share, reserved for issuance pursuant to options outstanding under the 2009 Share Incentive Plan   (3)   Other   41,790   $ 1.9475   $ 81,386.03   0.0001381   $ 11.24
                                       
Total Offering Amounts:   $ 3,295,018.10         455.04
Total Fee Offsets:               0.00
Net Fee Due:             $ 455.04

 

__________________________________________
Offering Note(s)

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also includes an indeterminate number of additional shares that become issuable under the 2024 Share Option Plan and the 2009 Share Incentive Plan as a result of anti-dilution provisions described therein by reason of any dividend, share split, recapitalization or other similar transaction effected without the receipt of consideration leading to an increase in the number of outstanding shares.

Estimated solely for purposes of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act, based upon the average of the high ($2.04) and low ($1.855) sales prices of the registrant’s ordinary shares as reported on the NYSE American on August 7, 2026.
(2) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also includes an indeterminate number of additional shares that become issuable under the 2024 Share Option Plan and the 2009 Share Incentive Plan as a result of anti-dilution provisions described therein by reason of any dividend, share split, recapitalization or other similar transaction effected without the receipt of consideration leading to an increase in the number of outstanding shares.
(3) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also includes an indeterminate number of additional shares that become issuable under the 2024 Share Option Plan and the 2009 Share Incentive Plan as a result of anti-dilution provisions described therein by reason of any dividend, share split, recapitalization or other similar transaction effected without the receipt of consideration leading to an increase in the number of outstanding shares.